Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma

Lenvatinib is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), but the effect of dose modification on its efficacy is unclear. We analyzed the relationship between the relative dose intensity during the initial 4 weeks of therapy [4W-relative dose intensity (RDI)] and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirino, Sakura, Tsuchiya, Kaoru, Kurosaki, Masayuki, Kaneko, Shun, Inada, Kento, Yamashita, Koji, Osawa, Leona, Hayakawa, Yuka, Sekiguchi, Shuhei, Okada, Mao, Wang, Wan, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Tamaki, Nobuharu, Yasui, Yutaka, Nakanishi, Hiroyuki, Itakura, Jun, Takahashi, Yuka, Asahina, Yasuhiro, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170221/
https://www.ncbi.nlm.nih.gov/pubmed/32310967
http://dx.doi.org/10.1371/journal.pone.0231828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170221/
https://www.ncbi.nlm.nih.gov/pubmed/32310967
http://dx.doi.org/10.1371/journal.pone.0231828

Ejemplares similares